Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer

URN zum Zitieren dieses Dokuments:: urn:nbn:de:bvb:355-epub-768287
DOI zum Zitieren dieses Dokuments:: 10.5283/epub.76828

Haas, Maximilian

; Mayr, Roman

; Sikic, Danijel ; Wullich, Bernd ; Klümper, Niklas ; Erben, Philipp ; Wirtz, Ralph ; Bolenz, Christian ; Roghmann, Florian ; Stöhr, Robert ; Bahlinger, Veronika ; Hartmann, Arndt ; Burger, Maximilian ; Breyer, Johannes

; Eckstein, Markus

Lizenz: Creative Commons Namensnennung-NichtKommerziell-KeineBearbeitung 4.0 International
PDF - Veröffentlichte Version
(1MB)

Veröffentlichungsdatum dieses Volltextes: 05 Jun 2025 04:22

Alternative Links zum Volltext:DOI Verlag

Details

Vorschau

Bibliographische Daten exportieren

Zusammenfassung

Zusammenfassung

Background and objective
Our aim was to provide a comprehensive analysis of the prevalence of potentially targetable activating FGFR3 alterations and their impact on oncological outcomes across different urothelial carcinoma (UC) stages.
Methods
We retrospectively analyzed clinical data and FGFR3 results for 1509 formalin-fixed, paraffin-embedded tissue specimens. Actionable activating FGFR3 mutations were assessed using a well-established multiplex SNaPshot polymerase chain reaction approach. FGFR3 fusion testing was performed with a Qiagen Therascreen kit.
Key findings and limitations
In the study population of 1509 patients, 202 (13%) had stage pTa, 380 (25%) had stage pT1, 258 (17%) had localized muscle-invasive bladder cancer (MIBC), 556 (37%) had locally advanced MIBC, 91 (6.0%) had metastatic UC of the bladder (mUCB), and 22 (1.5%) had metastatic upper tract UC (mUTUC). Of the FGFR3 alterations detected in 373 patients (25%), 104 (52%) were in stage pTa, 158 (42%) were in pT1, 42 (16%) were in localized MIBC, 53 (9.5%) were in locally advanced MIBC, nine (9.9%) were in mUCB, and seven (32%) were in mUTUC. FGFR3 alterations were associated with better progression-free survival and overall survival in the overall population (p < 0.001), but not in subgroup analyses for different disease stages. Study limitations include the retrospective design and heterogeneous patient cohort.
Conclusions and clinical implications
FGFR3 alterations occur at a stage-dependent frequency and are more prevalent in lower tumor stages. We were unable to demonstrate an independent prognostic effect of FGFR3 alterations on oncological outcomes after adjusting for tumor stage.
Patient summary
We analyzed a protein called fibroblast growth factor receptor 3 (FGFR3) in patients with cancer of the urinary tract. We found that more aggressive tumors had fewer genetic changes in FGFR3 in comparison to less aggressive tumors. However, genetic changes in FGFR3 were not related to survival for these patients.

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Details

Vorschau

Bibliographische Daten exportieren

Zusammenfassung

Zusammenfassung

Downloadstatistik

Downloads

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Universitätsbibliothek